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Background: Sphingosine 1-phosphate (Sph-1-P), abundantly stored in platelets and released extracellularly upon
activation, plays important roles as an extracellular mediator by interacting with specific cell surface receptors,
especially in the area of vascular biology and immunology/hematology. Although the plasma Sph-1-P level is
reportedly determined by red blood cells (RBCs), but not platelets, this may not be true in cases where the platelets
have been substantially activated.
Methods and results: We measured the Sph-1-P and dihydrosphingosine 1-phosphate (DHSph-1-P) levels in serum
samples (in which the platelets had been fully activated) from subjects with (n = 21) and without (n = 33)
hematological disorders. We found that patients with essential thrombocythemia exhibited higher serum Sph-1-P
and DHSph-1-P concentrations. The serum Sph-1-P concentration was closely correlated with the platelet count but
was very weakly correlated with the RBC count. Similar results were obtained for DHSph-1-P. The serum Sph-1-P
and DHSph-1-P levels were inversely correlated with the level of autotaxin (ATX), a lysophosphatidic acid-producing
enzyme. A multiple regression analysis also revealed that the platelet count had the greatest explanatory impact on
the serum Sph-1-P level.
Conclusions: Our present results showed close correlations between both the serum Sph-1-P and DHSph-1-P levels
and the platelet count (but not the RBC count); these results suggest that high concentrations of these sphingoid
base phosphates may be released from platelets and may mediate cross talk between platelet activation and the
formation of atherosclerotic lesions.
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Sphingosine 1-phosphate (Sph-1-P) has been shown to
be an important lipid mediator in the fields of vascular
biology and immunology/hematology [1]. Although Sph-
1-P has been demonstrated to act as an intracellular me-
diator, most of the physiological functions of Sph-1-P
are exerted through S1P receptors located on the plasma* Correspondence: yatoyuta-tky@umin.ac.jp
1Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo,
Japan
2Department of Clinical Laboratory Medicine, Graduate School of Medicine,
The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
Full list of author information is available at the end of the article
© 2013 Ono et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormembrane [2,3]. Therefore, elucidating the mechanism
that regulates plasma Sph-1-P levels is an important
task. Regarding the source of Sph-1-P in plasma, a previ-
ous report proposed that the plasma circulating Sph-1-P
level might be determined by platelets, since Sph-1-P is
abundantly accumulated in platelets [4]. However, from
experiments using genetically modified mice models [5]
and analyses in human subjects [6], the plasma Sph-1-P
level is now thought to be determined not by platelets,
but mainly by erythrocytes. This theory seems plausible
because the circulating volume of erythrocytes is much
greater than that of platelets.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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levels during the steady state in healthy subjects,
however, platelets may also play an important role
during pathological states in which the platelets
are activated, such as in thrombosis. Regarding this pos-
sibility, the clinical significance of Sph-1-P in athero-
sclerotic diseases differs depending on the type of
samples in which the Sph-1-P level is measured: plasma
HDL-linked Sph-1-P, albumin-linked Sph-1-P, or serum
Sph-1-P. Clinical studies investigating Sph-1-P levels in
atherosclerotic diseases have reported that although
HDL linked Sph-1-P is negatively related with athero-
sclerosis [7,8], Sph-1-P in non-HDL fractions and serum
Sph-1-P are positively correlated with atherosclerosis
[7,9]. This discrepancy might be explained by the differ-
ent origin of Sph-1-P in these samples; contrary to
plasma samples in which the Sph-1-P levels are mainly
determined by erythrocyte-derived Sph-1-P, platelets can
have a large impact on the Sph-1-P concentration
in serum samples in which the platelets are fully acti-
vated. If true and considering that Sph-1-P released
from platelets might be preferably carried on albumin
(non-HDL fraction) [10,11], these results suggest that
platelet-derived Sph-1-P might exert proatherosclerotic
properties. To our knowledge, the factors that determine
the serum Sph-1-P levels have not yet been elucidated.
In the present study examining serum samples from sub-
jects with and without hematological disorders, we investi-
gated the factors that determine the serum Sph-1-P levels.
We also examined dihydrosphingosine 1-phosphate
(DH-Sph-1-P), which is considered to work as an agon-
ist against Sph-1-P receptors [12].Figure 1 Serum Sph-1-P and DHSph-1-P levels in non-hematological d
samples were collected from the patients described in Table 1 and the ser
the NHD (non-hematological disorder) group and P<0.01 vs. ET (essential t
P<0.05 vs. VWD (von Willebrand diseases), ‡P<0.05 vs. NHD and P<0.01 vs.
purpura) and P<0.05 vs. VWD.Results
Serum Sph-1-P and DHSph-1-P levels were increased in
patients with essential thrombocythemia (ET)
To elucidate which factors determine the serum Sph-1-P
and DHSph-1-P levels, we first measured the serum
Sph-1-P and DHSph-1-P levels in subjects with
hematological disorders and with non-hematological dis-
orders (NHD) (Figure 1). The basic characteristics of the
subjects are shown in Table 1. As predicted by the fact
that erythrocytes determine the plasma Sph-1-P levels to
a large degree [6], the serum Sph-1-P levels were lower
in the aplastic anemia (AA) group, which had a signifi-
cantly lower RBC count, compared with the other
groups. Importantly, the ET group had a significantly
higher Sph-1-P and DHSph-1-P level, although the RBC
count was similar to those of the other groups except
for the AA group. The platelet count for the ET group
was much higher than those in the other groups
(Table 1). Therefore, these results suggested that platelet
count might also determine the serum Sph-1-P and
DHSph-1-P levels.
Serum Sph-1-P and DHSph-1-P concentrations were more
positively related with the platelet count than with the
RBC count
Next, we compared the serum Sph-1-P and DHSph-1-P
levels with the RBC count or the platelet count. As
shown in Figure 2B, the serum concentration of Sph-1-P
was significantly correlated with the RBC count (r =
0.393, P = 0.003). However, unlike the plasma Sph-1-P
level, the serum Sph-1-P level was more significantly
correlated with the platelet count (r = 0.775, P<0.001,isorder subjects and subjects with hematologic diseases. Serum
um Sph-1-P (A) and DHSph-1-P levels (B) were measured. *P<0.05 vs.
hrombocythemia). †P<0.01 vs. AA (aplastic anemia) and NHD and
ET, §P<0.01 vs. NHD, AA, and ITP (idiopathic thrombocytopenia
Table 1 Basic characteristics of the subjects
RBC (X104/μL) Platelets (X104/μL) alb (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) TG (mg/dL) ATX (ng/mL)
AA 215.0 ± 9.9* 2.8 ± 0.5 4.4 ± 0.1 54.8 ± 14.6 103.6 ± 35.4 178.5 ± 200.1 1.49 ± 0.39
ET 467.9 ± 101.2 84.8 ± 35.4† 4.2 ± 0.2 56.8 ± 14.4 104.5 ± 40.4 144.7 ± 66.5 0.96 ± 0.13
ITP 472.2 ± 40.1 3.1 ± 1.1 4.1 ± 0.4 57.9 ± 15.7 100.9 ± 25.9 164.2 ± 127.3 0.96 ± 0.13
VWD 423.0 ± 89.9 27.5 ± 6.3 4.4 ± 0.2 28.9 ± 0.4 73.9 ± 59.9 127.7 ± 29.6 0.95 ± 0.12
NHD 436.4 ± 71.8 22.1 ± 8.2 4.1 ± 0.5 40.3 ± 19.0 127.4 ± 53.5 135.7 ± 71.7 0.90 ± 0.07
All 437.3 ± 86.6 31.2 ± 31.1 4.1 ± 0.4 45.1 ± 18.9 116.0 ± 49.6 140.3 ± 78.7 0.95 ± 0.05
Serum samples were collected from subjects with NHD (non-hematological disorders, n=33) and patients with AA (aplastic anemia, n=2), ET
(essential thrombocythemia, n=10), ITP (idiopathic thrombocytopenia purpura, n=6), and VWD (von Willebrand diseases, n=3). ATX represents autotaxin. Data were
shown as the mean ± SD.
* P<0.01 vs. ET, ITP, NHD, and P<0.05 vs. VWD; †P<0.01 vs. the other groups.
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were observed for the serum DHSph-1-P level (Figure 2C
and D). These results suggested that the serum Sph-1-P
and the DHSph-1-P levels might derive largely from ac-
tivated platelets in prepared serum samples.
We also evaluated the correlation between the serum
Sph-1-P level and the platelet count in NHD subjects orFigure 2 Correlations between serum Sph-1-P level or serum DHSph-
correlations between the serum Sph-1-P level and the platelet count (A) an
platelet count (C) and the RBC count (D) in all subjects (n = 54) are shownsubjects with hematological disorders separately. In sam-
ples from NHD subjects alone, a close correlation be-
tween the Sph-1-P or DHSph-1-P level and the platelet
count was observed (r = 0.668, P<0.001, Figure 3A; r =
0.587, P<0.001, respectively). Also in samples from sub-
jects with hematological disorders, a significant close
correlation between the Sph-1-P level and the platelet1-P level and platelet count or RBC count in all subjects. The
d the RBC count (B) and between the serum DHSph-1-P level and the
.
Figure 3 Correlations between serum Sph-1-P level and platelet count in subjects and in subjects with NHD and with hematological
disorders. The correlations between the serum Sph-1-P level and the platelet count in NHD subjects (n = 33) (A), and in subjects with
hematological disorders (n= 21) (B) are shown.
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These results suggest that the serum Sph-1-P and
DHSph-1-P levels are mainly determined by the platelet
count irrespective of the presence of hematological
disorders.
Serum Sph-1-P and DHSph-1-P concentrations were
inversely related with the serum ATX level
We further investigated possible determinants of the Sph-
1-P and DHSph-1-P concentrations. First, we investigated
the correlation of Sph-1-P or DHSph-1-P with the HDL
cholesterol and albumin levels, since Sph-1-P is mostly
bound to HDL or albumin in plasma [13,14]. However, noFigure 4 Correlations between the serum Sph-1-P level or the DHSph
Sph-1-P level (A) or the DHSph-1-P (B) level and the ATX level in all subjecsignificant correlations were observed with HDL choles-
terol and albumin levels (data not shown).
We next evaluated the correlation between Sph-1-P or
DHSph-1-P and the autotaxin (ATX) level. ATX is a key
enzyme in the production of lysophosphatidic acid (LPA)
from lysophosphatidylcholine (LPC) [15,16]. Along with
LPA synthesis, Sph-1-P and DHSph-1-P can theoretically
be formed with ATX from sphingosylphosphorylcholine
(SPC) [17]. However, contrary to our expectations, the
serum ATX level was significantly and inversely related to
the serum Sph-1-P and DHSph-1-P concentrations (r = -0
.407, P = 0.010 and r = -0.452, P<0.001, respectively)
(Figure 4A and B).-1-P level and the ATX level. The correlations between the serum
ts (n = 39) are shown.
Table 3 Multiple regression analysis for serum DHSph-1-P
level in all the subjects
b 95% CI Standardized β P value
Platelets 1.41 (0.73 - 2.09) 0.532 <0.001
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count was the most important explanatory variable
determining the serum Sph-1-P and DHSph-1-P
concentrations
Finally, we performed a multiple regression analysis util-
izing the serum Sph-1-P or DHSph-1-P level as the ob-
jective variable, as mentioned in the Materials and
methods section. As predicted from the correlation stud-
ies, the platelet count was the most important explana-
tory variable for the Sph-1-P concentration, followed by
the ATX level and RBC count in this order (Table 2). A
similar result was obtained for DHSph-1-P, except for
the RBC count (Table 3).Discussion
Sphingosine 1-phosphate (Sph-1-P) plays important roles
as an extracellular mediator through its interactions
with the G protein-coupled receptor S1P1-5, which is
expressed on the cell surface; these actions are especially
pertinent in the fields of vascular biology, immunology,
and hematology. Although erythrocytes are the major de-
terminant of the plasma Sph-1-P level [5,6], the major de-
terminant of the serum Sph-1-P concentration has not yet
been elucidated. In the present study, we attempted to elu-
cidate the source of serum Sph-1-P. We also investigated
the determinants of the DHSph-1-P concentration, which
are thought to act similarly as a ligand for Sph-1-P recep-
tors as Sph-1-P [12].
In this study, we demonstrated that the serum Sph-1-P
level was closely related to the platelet count (Figure 2).
This finding seems to be reasonable because when the re-
sults were adjusted according to the phospholipid level,
the platelets contained a higher concentration of Sph-1-P
than the erythrocytes [4] and the platelets were fully acti-
vated in the serum samples. Multiple regression studies
also revealed that the platelet count was the most explana-
tory variable for Sph-1-P (Table 2).
To our knowledge, this report is the first to demon-
strate that the serum Sph-1-P level is determined by the
platelet count. This result provides important clues re-
lated to the physiological properties of Sph-1-P inTable 2 Multiple regression analysis for serum Sph-1-P
level in all the subjects
b 95% CI Standardized β P value
Platelets 8.17 (6.44 - 9.91) 0.791 <0.001
ATX −196.40 (−361.46 - −31.35) −0.219 0.021




Albumin 0.857atherosclerotic diseases. In the physiological state, cells
involved in atherogenesis, such as endothelial cells, mac-
rophages, and smooth muscle cells, might be exposed to
Sph-1-P concentrations corresponding to the plasma
Sph-1-P level (300-500 nM). However, as reported in
this study, the Sph-1-P concentration in serum samples
in which the platelets are fully activated was much
higher (around 800 to 1,000 nM) than the plasma Sph-1
-P level. Therefore, cells are likely exposed to higher
concentrations of Sph-1-P at the exact site where throm-
bosis is occurring. This difference in the Sph-1-P con-
centrations between plasma and the exact site of
thrombosis may explain the apparently contradictory
clinical influences of serum Sph-1-P and plasma Sph-1-P
on atherosclerosis [7-9]. According to the results from
in vitro experiments, Sph-1-P exerts anti-atherosclerotic
properties such as the induction of NO production [18],
the suppression of TNF-?-induced VCAM-1 induction
[19], and the inhibition of the adhesion of monocytes on
the endothelium through the rearrangement of endothe-
lial integrins [20] at concentrations up to several hun-
dred nM; meanwhile, Sph-1-P can induce adhesion
molecules by activating nuclear factor κ-B [19,21,22] and
activate platelets [23,24] at concentrations higher than
several μM. Therefore, Sph-1-P can create a vicious cycle
formed by local thrombosis in atherosclerotic lesions;
platelets are activated in the atherosclerotic lesions and
Sph-1-P is released from the platelets, and then the high
concentration of Sph-1-P accelerates atherosclerosis and
further activates platelets. Further clinical and basic
studies are needed to elucidate the association between
serum Sph-1-P and atherosclerotic diseases as well as
the possible existence of other unknown factors deter-
mining the release of Sph-1-P from platelets.
Concerning this issue, interesting relationships be-
tween the serum Sph-1-P and ATX levels were observed
in the present study. ATX is a key enzyme in the pro-
duction of LPA; LPA is hydrolyzed from LPC by ATX/
lysophospholipase D (LysoPLD) [15,16]. Along with
these functions, ATX is known to hydrolyze SPC to pro-
duce Sph-1-P [17], although the contribution of this
pathway to Sph-1-P might be much smaller than the
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into Sph-1-P, considering the concentration of SPC
in vivo. Therefore, the observation of an inverse correl-
ation between Sph-1-P and ATX seems contradictory.
One possible mechanism is that substrates produced by
ATX, such as LPA, might be involved in the formation
of Sph-1-P. Further studies are needed to examine this
possibility.
In this study, we measured the serum DHSph-1-P level
as well as the serum Sph-1-P level. DHSph-1-P was
shown to behave as an Sph-1-P receptor agonist similar
to Sph-1-P [12]; however, little information is available
regarding the modulation of the in vivo DHSph-1-P
level. As shown in Figures 1, 2 and 4, and Table 3, we
demonstrated that the serum DHSph-1-P level was de-
termined in a manner similar to the Sph-1-P level.
In summary, this study demonstrated that the serum
Sph-1-P and DHSph-1-P levels were determined mainly
by the platelet count and suggested that the high con-
centrations of Sph-1-P released from platelets might me-
diate cross talk between platelet activation and the
formation of atherosclerotic lesions.
Materials & methods
Serum sample preparation
Non-hematological disorder subjects [NHD] (n = 33)
and patients with aplastic anemia [AA] (n = 2), essential
thrombocythemia [ET] (diagnosed according to the
WHO classification criteria [25]) (n = 10), idiopathic
thrombocytopenia purpura [ITP] (n = 6), and von
Willebrand diseases [VWD] (n = 3) were enrolled.
The serum samples used in this study were residual
samples of those obtained after the completion of rou-
tine laboratory analyses. The study was approved by the
Institutional Research Ethics Committee of the Faculty
of Medicine, the University of Tokyo.
Measurement of Sph-1-P and DHSph-1-P
Sph-1-P and DHSph-1-P in serum samples were extracted
using a two-step extraction method and were measured
using high-performance liquid chromatography (HPLC)
using C17-Sph-1-P as an internal standard, as previously
described [26].
Measurement of serum autotaxin levels
The autotaxin (ATX) antigen levels in the serum were de-
termined using a two-site immunoenzymetric assay with
the ATX assay reagent and the TOSOH AIA system
(TOSOH, Tokyo, Japan) [27].
Statistical analysis
All the data were statistically analyzed using SPSS (Chicago,
IL). The results were expressed as the mean ± SD. Values
obtained from more than three groups were comparedusing a one-way analysis of variance (ANOVA) followed by
a post-hoc test. Correlations were evaluated using the Pear-
son correlation. The independent effects of the RBC count,
platelet count, albumin, ATX, HDL-C, LDL-C, and TG
levels on the serum Sph-1-P or DHSph-1-P levels
were evaluated using stepwise multiple regression analyses.
P-values less than 0.05 were deemed statistically significant
for all the analyses.
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